Nath Bio-Genes (India) Limited (NATHBIOGEN) Fair Value & Analysis
Basic Materials · IN · Market cap ₹3.1B
Fair value as of: Aug 13, 2026
From 17 valuation models · updated 4 days ago
Fair value updated Aug 13, 2026, revised from ₹255.22 to ₹230.04 (−9.9%) since Aug 8, 2026. Share price −3.5% over the past month.
Below-average quality, screening 49% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (₹230.04). The market is more pessimistic than our downside scenario.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹129.02 – ₹422.02 · fair‑value band ₹230.04 – ₹271.57 · the ₹154.43 price screens below the ₹230.04 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Nath Bio-Genes (India) Limited (NATHBIOGEN) currently trades at ₹154.43, while our model-based Fair Value estimate is ₹230.04, implying the stock looks roughly 49.0% undervalued today. The Quality Score stands at 43/100 (below-average quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Nath Bio-Genes (India) Limited generated revenue of ₹4.5B at a net margin of 9.4%. Revenue declined 1.0% year over year. It earns a return on equity of 6.3%. Net debt stands at ₹625M. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹230.04 (bear case) to ₹271.57 (bull case); at ₹154.43, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -17% fair-value upside, at 49%, NATHBIOGEN screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: DCF Models (₹483.98) versus Dividend Discount (₹30.25). Highest evidence: Residual Income (76).
Notify me when NATHBIOGEN reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 41
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities.
Full company description
Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers fiber and oil seeds, including cotton and mustard; plant nutrient supplements; pearl millets; seeds for field crops, such as bajra, maize, corn, paddy, wheat, and jowar; and seeds for vegetables comprising chilli, okra, tomato, bitter gourd, and cucumber. It also provides crop protection supplements under the Win-chi-Win, WinGoli, and WinPro Granules brands; and forage seeds under the NUTRIMAX GOLD and NUTRIMAX brand names. The company was founded in 1979 and is based in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Nath Bio-Genes (India) Limited reported revenue of ₹4.5B in FY2026 versus ₹2.8B in FY2022, a compound +12.5%/yr. Reported net income was ₹416M in FY2026.
of which total revenue +8.3 pp · buybacks/dilution −2.3 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch NATHBIOGEN: get an alert when its fair value changes →
Peer Group
Agricultural Inputs · 177 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Agricultural Inputs median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Corteva, Inc CTVA | $76.22 | $27.81 | -64% |
| Nutrien Ltd NTR | C$93.60 | C$81.69 | -13% |
| Qinghai Salt Lake Industry Co 000792 | ¥27.65 | ¥21.26 | -23% |
| CF Industries Holdings CF | $120.01 | $161.00 | +34% |
| SABIC Agri-Nutrients Company 2020 | 122.90 SAR | 127.31 SAR | +4% |
| Yara International ASA YAR | kr 418.10 | kr 67.25 | -84% |
| Yunnan Yuntianhua Co 600096 | ¥29.82 | ¥42.12 | +41% |
| Asia-potash International Investment (Guangzhou)Co.,Ltd., 000893 | ¥45.86 | ¥38.01 | -17% |
| Coromandel International Limited COROMANDEL | ₹2,089 | ₹1,129 | -46% |
| UPL Limited UPL | ₹570.50 | ₹387.06 | -32% |
Compare Nath Bio-Genes (India) Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Nath Bio-Genes (India) Limited (NATHBIOGEN) overvalued or undervalued?
What is the fair value of NATHBIOGEN?
What is the quality score of NATHBIOGEN?
What is the revenue of Nath Bio-Genes (India) Limited (NATHBIOGEN)?
What is the net profit margin of NATHBIOGEN?
Does Nath Bio-Genes (India) Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Nath Bio-Genes (India) Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.